Healthcare Industry News: Central Venous Catheter
News Release - August 31, 2009
Hospira Receives FDA Approval for Six New Presentations of HeparinHeparin Product Offering Now Among Broadest Available
LAKE FOREST, Ill., Aug. 31 (Healthcare Sales & Marketing Network) -- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.
Heparin is used to prevent clot formation in Central Venous Catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for different modes of administration. The six new vial presentations of heparin approved by the FDA range in volume from one milliliter to 30 milliliters, and in concentration from 1,000 units per milliliter to 10,000 units per milliliter.
Hospira recognizes the clinical need for this important medication and sought to expand its marketed portfolio of heparin presentations to help meet market demand. With the addition of the new vials, Hospira now offers one of the broadest portfolios of heparin available on the U.S. market, with various sizes and strengths of the product available in syringes, vials and flexible containers.
"Hospira is committed to ensuring patient access to safe and effective supplies of heparin," said Joshua Gordon, vice president, Specialty Pharmaceuticals, Hospira. "These additional presentations will provide our customers a wide range of options to address the continuum of care."
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.